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The complement system is a major component of humoral innate immunity, acting as a
first line of defense against microbes via opsonization and lysis of pathogens. However,
novel roles of the complement system in inflammatory and immunological processes,
including in cancer, are emerging. Endometriosis (EM), a benign disease characterized by
ectopic endometrial implants, shows certain unique features of cancer, such as the
capacity to invade surrounding tissues, and in severe cases, metastatic properties. A
defective immune surveillance against autologous tissue deposited in the peritoneal cavity
allows immune escape for endometriotic lesions. There is evidence that the glandular
epithelial cells found in endometriotic implants produce and secrete the complement
component C3. Here, we show, using immunofluorescence and RT-qPCR, the presence
of locally synthesized C3 in the ectopic endometriotic tissue, but not in the eutopic tissue.
We generated a murine model of EM via injection of minced uterine tissue from a donor
mouse into the peritoneum of recipient mice. The wild type mice showed greater amount
of cyst formation in the peritoneum compared to C3 knock-out mice. Peritoneal washings
from the wild type mice with EM showed more degranulated mast cells compared to C3
knock-out mice, consistent with higher C3a levels in the peritoneal fluid of EM patients. We
provide evidence that C3a participates in an auto-amplifying loop leading to mast cell
infiltration and activation, which is pathogenic in EM. Thus, C3 can be considered amarker
of EM and its local synthesis can promote the engraftment of the endometriotic cysts.
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Endometriosis (EM) is a chronic gynecological disorder,
frequently associated with infertility, that affects about 5-10%
of women in reproductive age (1, 2). EM is characterized by
severe pain, dysmenorrhea, dyspareunia and dysuria, as a
consequence of the presence of functional endometrial tissue
outside the uterine cavity (3). The most common locations for
the ectopic implants are the ovaries, peritoneum, and the utero-
sacral ligaments. The presence of ectopic tissues in these areas
induces a condition of chronic inflammation. Current evidence
suggests that immune dysfunction is the most likely causative
factor for the EM pathogenesis (4–6). In particular, the pathways
involved in immune cell recruitment, cell adhesion, and
inflammatory processes encourage the implantation and
survival of endometriotic lesions.
The current consensus is that EM involves a local pelvic
inflammatory process with altered functions of immune-related
cells in the peritoneal environment (7). Recent studies suggest
that the peritoneal fluid (PF) of women with EM contains an
increased number of activated macrophages that secrete various
humoral mediators locally, including growth factors, cytokines
and possibly, oxidative products (8), leading to the development
and progression of EM and EM-associated infertility (9).
Although the contributions of specific immune cell subsets and
their mediators to the onset and the course of the inflammatory
process in endometrial lesions are still poorly understood,
evidence suggests that mast cells (MCs) are crucially involved
in the inflammatory process associated with EM. In fact, high
numbers of degranulated MCs have been found in endometriotic
lesions (10–12).
Recently, it has been shown that one of the most predominant
pathways altered in EM is the complement system (13, 14). The
complement system is an important part of the innate immunity
and acts as a bridge between innate and adaptive immuneFrontiers in Immunology | www.frontiersin.org 2system. It is involved in host defense against infectious agents
and altered self. Three different molecules are responsible for the
recognition phase of complement: C1q, Mannose-Binding Lectin
(MBL), and C3. The binding of the recognition molecules to the
target ligands initiates the three different complement pathways:
the classical (via C1q), alternative (via C3) and lectin (via MBL)
pathway (15, 16). The three pathways eventually converge in the
formation of the C3 and C5 convertases. This then results in the
generation of the main effector molecules of the complement
system: the opsonins C3b and C4b, the anaphylatoxins C3a, C4a
and C5a, and the Membrane Attack Complex (MAC) that causes
the target cell lysis. The small complement fragments,
anaphylatoxins, cause local inflammatory responses by acting,
for instance, on MCs, inducing an increase in blood flow,
vascular permeability, and leukocyte recruitment (17).
The presence of the complement component C3 in endometriotic
tissues has been reported since 1980 (18, 19). However, from 1980 to
date, no significant progress has been made in understanding the
reasons for C3 presence in the endometriotic microenvironment and
the role it played in the development of lesions. All currently available
therapies for EM are not etiological but symptomatic treatments,
accounting just for a partial and transitory relief of the symptoms
(20). The prevalent therapeutic options for EM-associated pain are
represented by contraceptive rather than fertility-promoting
treatments (21). Immunotherapy is beginning to be considered as
an option for EM. In the light of the possibility to use complement
immunotherapy with blocking antibodies in EM (22), we examined
the underlying mechanisms of C3 expression and its cellular cross-
talk, making it a novel potential therapeutic target for EM.
The pathophysiology of EM is an excellent example of immune
dysfunction reminiscent of tumour microenvironment, and
strongly connected with infertility. Here, we aimed to investigate
the interplay between C3 and MCs, and their involvement in the
pathogenesis of EM, through the development of in vitro and
in vivomodels.August 2021 | Volume 12 | Article 693118
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Patients
Patients and control women were enrolled at the Institute for
Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy.
The study was reviewed and approved by the Regional Ethical
Committee of FVG (CEUR), Udine, Italy (Prot. 0010144/P/
GEN/ARCS 2019). Informed consent for participation in the
study was obtained from all participants. The study group
consisted of a total of 7 women, diagnosed with moderate/
severe and minimal/mild EM, according to the revised criteria
of the American Society for Reproductive Medicine (23).
Cell Lines
HepG2, AN3CA and THP-1 cell lines were obtained from
American Type Culture Collection (ATCC). HMC-1 cells were
kindly provided by Prof. Carlo Pucillo (University of Udine,
Italy). AN3CA and HepG2 cells were cultured in DMEM/F12,
HMC-1 and THP-1 in RPMI-1640, both media were
supplemented with 10% v/v FBS. THP-1 cells were
differentiated into macrophage-like phenotype by adding
15 ng/mL of Phorbol 12-Myristate 13-Acetate (PMA; Sigma)
in RPMI-1640 complete medium for 48 h at 37°C in 5% v/v CO2.
The medium always contained 100 U/mL penicillin and
100 mg/mL of streptomycin.
Primary Cell Isolation and Culture
Primary endometriotic cells were isolated from EM patient
lesions. Briefly, tissues were digested overnight (ON) at 4°C
with 0.25% trypsin (Sigma-Aldrich), 50 mg/mL DNase 1 (Roche,
Milan, Italy) in PBS and then treated with collagenase type I (3
mg/mL; Worthington Biochemical) for 30 min at 37°C. As
described earlier (24), endothelial cells (EECs) were positively
selected with Dynabeads M-450 (Life Technologies, Milan, Italy)
coated with Ulex europaeus 1 lectin (Sigma-Aldrich), seeded on
12,5 cm2 flask precoated with 2 µg/cm2 fibronectin (Roche). Cells
were maintained in serum-free endothelial basal medium (Life
Technologies, Monza, Italy), supplemented with 20 ng/mL bFGF
(basic Fibroblast Growth Factor), 10 ng/mL EGF (Epidermal
Growth Factor), 10% v/v FBS (all from Life Technologies), and
10% v/v heat inactivated human serum and incubated at 37°C,
5% CO2. Endometriotic epithelial/stromal cells (EM cells),
obtained via the negative selection, were cultured in the same
medium containing only 10% FBS.
Moreover, uterine microvascular endothelial cells (UtMECs)
were isolated from normal uterus of healthy women, following
the same procedure.
Murine Model of EM
C57BL/6 WT mice were purchased from Harlan Laboratories.
C3-/- mice were kindly provided by Prof. Marina Botto, Centre
for Complement and Inflammation Research, Department of
Medicine, Imperial College, London, UK and generated as
described previously (25). All animals were handled in
accordance with the institutional guidelines and in compliance
with the European (86/609/EEC) and the Italian (D.L.116/92)
laws. The Institutional Animal Care Committee of the UniversityFrontiers in Immunology | www.frontiersin.org 3of Trieste approved the procedures (Prot. 35/2010B). The mouse
model of EM was adapted from Somigliana and Mariani (26, 27).
Briefly, donor mice were injected with 17-b-estradiol-3-benzoate
(Sigma-Aldrich; 100 µg/Kg i.m.) and sacrificed 1 week later; the
uterus was removed, the two horns were isolated, the
myometrium was removed by scraping, and the remaining
endometrial tissue was reduced to small fragments with
scissors. The fragments derived from the isolated uterine horns
were weighed and suspended in 400 µl saline (1 mg/ml); half of
the preparation was injected into the peritoneum of each of two
recipient mice with a syringe (Day 0). Carprofen (5 mg/kg body
weight) was given as an analgesic immediately after the surgery
and again after 48 h. Hormonal therapy with 17-b-estradiol-3-
benzoate (Sigma-Aldrich, 50 µg/kg i.m.) was initiated at the time
of tissue injection and at 2-day interval thereafter. Mice were
sacrificed on day 21 via administration of a lethal dose of
anesthetic, their abdomen was opened, and the presence of the
lesions was evaluated by an operator blinded to the different
conditions. Translucid isolated or grouped superficial lesions
were mainly found on the abdominal wall, on the epiploon and
around the uterus. Deeply infiltrating lesions were never
observed in this model. In some cases, lesions resembling
human chocolate cysts were found.
Characterization of EM Cells
EM cells were plated on 8-chamber culture slides (BD Biosciences
Discovery Labware, Milan, Italy). Cells, when grown to confluence,
were fixed and permeabilized with FIX & PERM (Società Italiana
Chimici, Rome, Italy). Next, cells were incubated with primary
monoclonal antibody (mAb) (clone 9) mouse anti-human vimentin
(Sigma-Aldrich), (cloneF8/86) mouse anti-human vWF (Dako-
Cytomation, Milan, Italy), or mouse anti-human CK 8/18
(Abcam, Italia, Milan, Italy) for 1 h at room temperature (RT),
followed by fluorescein isothiocyanate (FITC)-conjugated goat anti-
mouse IgG for 1 h at RT. Images were acquired using Leica
DM3000 microscope (Leica, Wetzlar, Germany) and collated
using a Leica DFC320 digital camera (Leica).
Gene Expression Analysis
RNA was extracted from cells using kit supplied by Norgen
Biotek Corp. (Aurogene, Rome, Italy) according to the supplier’s
instructions and reverse transcripted to cDNA through
SuperMix kit (Bioline). qPCR was carried out on a Rotor-Gene
6000 (Corbett, Qiagen, Milan, Italy) using SYBR™ Green PCR
Master Mix (Applied Biosystems, Milan, Italy). Supplementary
Table 1 shows the primers used for RT-qPCR. The melting curve
was recorded between 55°C and 99°C with a hold every 2s. The
relative amount of gene expression in each sample was
determined by the Comparative Quantification (CQ) method
supplied as a part of the Rotor Gene 1.7 software (Corbett
Research) (28). The relative amount of each gene was
normalized with 18S and expressed as arbitrary units (AU),
considering 1 AU obtained from HepG2 cells as a calibrator.
Western Blot Analysis
106 AN3CA cells seeded onto 6-well plates were treated with 100
ng/mL of TNF-a or 5 ng/mL of IL-1b for 36 h. Cell lysates wereAugust 2021 | Volume 12 | Article 693118
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transferred to a nitrocellulose membrane using the semi-dry
transfer apparatus Trans-Blot Turbo System according to the
manufacturer’s protocol (BIO-RAD). 100 ng of recombinant
human C3 (Quidel) was used as a control. After 1 h of
incubation with 5% skimmed milk in TBST (10 mM Tris, pH
8.0, 150 mM NaCl, 0.5% Tween 20), the membrane was probed
with 1:500 anti-C3 (MyBioSource) ON at 4°C. Membrane was
washed three times for 5 min and incubated with 1:10000 anti-
goat LI-COR IRDye 800CW for 1h at RT. After three washing
steps, the fluorescence intensity was acquired by the Odyssey®
CLx near-infrared scanner (LI-COR Biosciences, Lincoln, NE,
USA). Image acquisition, processing and data analysis were
performed with Image Studio Ver 5.2 (LI-COR Biosciences).
Measurement of C3a
The levels of C3a in PFs from EM patients (n = 16) and from
control patients (n = 8), and C3 in cell culture supernatant were
evaluated by ELISA kits purchased from Quidel.
Co-Culture and Cell Stimulation
A confluent 24 well-plate of AN3CA cells was stimulated ON
with 100 ng/mL of TNF-a, or 5 ng/mL of IL-1b (both from
PeproTech, ListerFish, Milan, Italy), or 10% of pooled EM-PF.
For the co-culture study, the cells were seeded at confluence, in
the lower part of a 1µm pore TW system (Corning, Milan, Italy),
whereas HMC-1 or THP-1 (2x105/TW) were present in the
upper part, in the presence of 10% of pooled EM-PF, with or
without blocking anti-human C3a (clone H13, 20 µg/mL;
MyBiosource, Aurogene, Milan, Italy) (29). Subsequently, the
cells were lysed for RNA extraction, the supernatant recovered
and stored at -80°C.
Immunohistochemical Analysis
Uterine and ectopic endometrial tissues were used in this study,
after approval by the University Hospital of Palermo Ethical
Review Board (approval number 09/2018). Our study selected
two cases of proliferative and secretory endometrium as controls,
and two cases of patients with tubal and abdominal
wall endometriosis.
Immunohistochemistry (IHC) was performed using a
polymer detection method. Briefly, tissue samples were fixed in
10% v/v buffered formalin and then paraffin embedded. 4 µm-
thick tissue sections were deparaffinized and rehydrated. The
antigen unmasking technique was performed using Novocastra
Epitope Retrieval Solutions, pH 6 EDTA-based (Leica
Biosystems) in thermostatic bath at 98°C for 30 min. Sections
were then brought to RT and washed in PBS. After neutralization
of the endogenous peroxidase with 3% v/v H2O2 and Fc blocking
by a specific protein block (Novocastra, Leica Biosystems),
samples were incubated for 1 h at RT with mouse anti-human
C3a/C3a (dilution 1:50, pH 6) monoclonal antibody (Millipore),
mouse anti-human C3aR (D-12; dilution 1:50, pH 6) monoclonal
antibody (Santa Cruz) and rabbit anti-human C3 (dilution 1:200,
pH 9) polyclonal antibody (Sigma-Merk). Staining was revealed via
polymer detection kit (Novocastra, Leica Biosystems) and AEC (3-
amino-9-ethylcarbazole), or DAB (3, 3’-diaminobenzidine)Frontiers in Immunology | www.frontiersin.org 4substrate chromogen, both purchased from Dako (Denmark).
Slides were counterstained with Harris Hematoxylin (Novocastra,
Leica Biosystems). Toluidine blue stain was carried out to detect the
presence of mast cells in uterine and ectopic endometrial tissues,
according to the manufacturer’s kit Histoline. Slides were analyzed
under the Axio Scope A1 optical microscope (Zeiss) and
microphotographs were collected through the Axiocam 503 color
digital camera (Zeiss) using the Zen2 software. Quantitative
analyses of C3 IHC staining were performed by calculating the
average percentage of positive signals in five non-overlapping fields
for each sample (normal endometrium, n = 3; ovarian EM, n = 3;
adnexal EM, n = 3; peritoneal EM, n = 3) at medium-power




Tryptase ELISA kit (USCN, Life Sciences Inc) was used to
determine the concentration of tryptase in mice PF samples.
The assays were performed according to the manufacturer’s
instructions and the results referred to a calibration curve
expressed in ng/mL. Samples were assayed in triplicate.
Gene Expression Profiling (GEP) Analysis
The expression levels of C3 and C3AR1 genes in control
endometrium and various EM lesions (peritoneal, deep and
ovarian EM) were analyzed using data extracted from the GEO
(Gene Expression Omnibus of the National Center for
Biotechnology Information-NCBI) with the series accession
number GSE141549. Microarray analysis on samples obtained
from 43 endometrium biopsies of healthy woman, 101
endometrium biopsies of EM patients and 190 EM lesions, and
data normalization, have been described by Gabriel and
colleagues (30).
Statistical Analysis
Data were analyzed by GraphPad Prism software 5.0 (GraphPad
Software Inc., La Jolla, CA, USA). Unpaired two-tailed Mann-
Whitney test was used for the analysis of different tissue C3 gene
expression and cells and for GEP analysis; Wilcoxon test was
applied for AN3CA stimulation and mouse model. Results were
expressed as mean ± SEM of three independent experiments
performed in duplicate. P-values <0.05 were considered
statistically significant.RESULTS
C3 Is More Abundant in Ectopic,
Compared to Eutopic, Endometrium and Is
Locally Expressed by Endometriotic Cells
We initially confirmed the presence of C3 in human
endometriotic tissue sections by immunofluorescence (IF,
Supplementary Figure 1) and by immunohistochemical assays
(IHC, Figure 1). IHC, using an anti-human C3 polyclonal
antibody, showed moderate cytoplasmic expression of C3 byAugust 2021 | Volume 12 | Article 693118
Agostinis et al. Role of C3 in EndometriosisFIGURE 1 | C3 is locally produced in human endometriotic tissue, which is up-regulated by pro-inflammatory cytokines. Representative microphotographs showing
expression of C3 by IHC in tubal (A), abdominal wall (B) and ovarian (C) endometriosis (EM). AEC (red) chromogen was used to visualize the binding of anti-human
C3 antibodies. Nuclei were counterstained in blue with Harris Hematoxylin; scale bars, 50mm. (D) Quantitative analyses of C3 IHC staining were carried out by
calculating the average percentage of positive signals in five non-overlapping fields for each sample (normal endometrium, n=3; ovarian EM, n=3; adnexal EM, n=3;
peritoneal EM, n=3) at medium-power magnification (200 x), using the Positive Pixel count v9, ImageScope software, as compared to control endometrium (CE).
Data are expressed as mean ± standard deviation. (E) Histogram representing C3 mRNA expression in CE, patient endometrium (PE) and in different EM lesions
(peritoneal, deep and ovarian EM). GEP analysis, based on data extracted from GEO (GSE141549), highlighted a significantly higher expression of C3 in EM lesions
as compared to CE. ***p < 0.001, ****p < 0.0001 (Mann-Whitney U Test). (F) The gene expression of C3 by EM tissue (n = 5) was investigated by RT-qPCR and
compared to normal endometrium (n= 5) using HepG2 hepatocyte cells as calibrator (AU = 1). 18S was used as the housekeeping gene. Data are expressed as
mean of at least three independent experiments ± standard error. *p < 0.05 (Mann-Whitney U Test). (G) The C3 mRNA expression was measured by RT-qPCR in
EM cells (n= 4) and compared to a normal endometrial cell line, AN3CA. Data are expressed as mean of at least three independent experiments ± standard error.
*p < 0.05 (Mann-Whitney U Test). (H) Protein levels of C3 were assessed by ELISA in the supernatant of EM cells (n=4) or AN3CA maintained in culture for 60 h.
Data are expressed as mean at least three independent experiments± standard error. (I) The stimulation of AN3CA cells with pro-inflammatory cytokines induced an
up-regulation of C3 expression. AN3CA cells were ON stimulated with TNF-a (100 ng/mL) or IL-1b (5 ng/mL) and the C3 expression was analyzed by RT-qPCR.
Data are expressed as mean of at least three independent experiments conducted in duplicate ± standard error. *p < 0.05 (Wilcoxon matched pairs test). (J) The expression
of C3 was examined in cell lysates by western blot analysis and the intensity of the bands was measured with Odyssey-LICOR scanner. (K)Measurement of C3 protein level
by ELISA in AN3CA cell culture supernatant stimulated for 36h with TNF-a (100ng/mL) or IL-1b (5ng/mL). Data are expressed as mean of three independent experiments
conducted in duplicate ± standard error. *p < 0.05.Frontiers in Immunology | www.frontiersin.org August 2021 | Volume 12 | Article 6931185
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cells in proliferative as well as secretory normal endometrium
(Supplementary Figure 2). C3 was found to be widely
distributed in the EM tissue, with variable intensity, ranging
from low in tubal EM, intermediate in abdominal wall EM and
high in ovarian EM (Figures 1A–D). C3 positivity was mostly
localized in the glandular-like structures (Supplementary
Figure 3 ; red arrows) and in the cytogen stroma
(Supplementary Figure 3; green arrows). As reported in
Figure 1E, the lower C3 expression in healthy or patient
derived endometrium as compared to EM lesions was
confirmed via GEP analysis.
In order to confirm the local synthesis of C3, total RNA was
isolated from ovarian EM cysts and eutopic endometrium. C3
gene expression was then analyzed by RT-qPCR, highlighting
higher expression levels of C3 transcript in ectopic EM tissues as
compared to normal endometrium (Figure 1F). HepG2
(hepatocyte cell line) was used as a calibration control.
To assess the contribution of EM epithelial cells to the local
C3 production, we isolated EM cells from human ovarian EM
cysts, showing marked positivity for both epithelial (cytokeratin
8/18) and stromal (vimentin) markers (Supplementary
Figure 4). RT-qPCR was performed to evaluate C3 expression
differences in isolated EM epithelial cells and AN3CA cells, as a
control of normal epithelial endometrial cells. Interestingly, EM
cells expressed a higher amount of C3 compared to AN3CA
(Figure 1G). In addition, only EM cells secreted the C3 protein
in the culture supernatant, as measured via ELISA (Figure 1H).
Since the IHC analysis also revealed a marked positivity in the
EM vessels, the expression of C3 was also investigated in EECs
and corresponding eutopic cells (UtMECs). We observed a very
low expression of C3 transcript by both endothelial cell types
(Supplementary Figure 5).
Pro-Inflammatory Stimuli Induce C3
Expression by Normal Endometrial Cell
Lines in an In Vitro Model of EM
In order to mimic the pro-inflammatory EMmicroenvironment, we
performed in vitro experiments, stimulating the endometrial cell
line AN3CA with pro-inflammatory cytokines. Our results
demonstrated that normal endometrial cells were able to produce
a very limited amount of C3 in resting conditions; however, when
cells were stimulated with TNF-a, or to a lesser extent with IL-1b,
we detected an increase in C3 mRNA levels by RT-qPCR
(Figure 1I) and C3 protein levels by western blot (Figure 1J and
Supplementary Figure 6). We also found that TNF-a stimulation
was able to increase the level of secreted C3 protein, as measured by
ELISA in cell supernatant (Figure 1K). Furthermore, we
demonstrated that the stimulation of C3 transcription induced by
TNF-a was dose-dependent (Supplementary Figure 7).
C3-/- Mice Are Refractory to Developing
EM Cysts in a Syngeneic In Vivo
Model of EM
To further investigate the role of C3 in EM pathogenesis, we set
up a syngeneic model of EM in C57BL/6 WT or C3 gene-Frontiers in Immunology | www.frontiersin.org 6deficient (C3-/-) mice. Estrus was induced in donor animals via
administration of estradiol. Then, the minced uterus of the donor
mice was injected in the peritoneum of recipient mice
(Figure 2A). After 3 weeks, the animals were sacrificed, and
the peritoneal cysts were counted. WT mice developed a higher
number of cysts compared to C3 deficient mice (Figure 2B).
Peritoneal Washings Isolated From WT
Mice With EM Present More Degranulated
MCs Compared to C3-/- Mice
We then analyzed the peritoneal washings of WT and C3-/- mice
for the presence of infiltrating leukocytes. The samples were
cytocentrifuged and the cells were stained with Giemsa. The
number of infiltrating leukocytes observed in the peritoneal
washings of both WT and C3-/- treated mice was comparable
with those observed in WT untreated (CTRL Untr) mice. A
similar number of total peritoneal MCs at baseline between
untreated WT and C3-/- mice has been already demonstrated
by Prodeus and colleagues (31). Surprisingly, the fluids collected
from the WT treated animals contained a lower number of MCs,
compared to the C3-/- treated mice (Figures 2C, D). Next, we
stained the cytocentrifuged leucocytes with a monoclonal
antibody to CD117, a marker of mature MCs. The peritoneal
washings collected from the WT mice contained CD117 positive
cells as well (Figure 2E). To confirm whether the MCs present in
WT peritoneal washings were degranulated, we measured the
levels of the MC enzyme, tryptase, in the murine peritoneal
washings. The ELISA demonstrated that WT mice with EM had
a higher amount of tryptase compared to C3-/- or CTRL
mice (Figure 2F).
C3a Level Is Higher in the PF of EM
Patients, Which Can Act on EM MCs
C3a is one of the most important stimuli for MC activation
(Figure 3A). Thus, we measured the levels of C3a in the PF of EM
patients (n = 16), and compared them with those obtained from
myoma and fibroma patients (women undergoing laparoscopy,
without alterations of peritoneal cavity environment, n = 8). Our
results showed that the PF of EM patients had significantly higher
level of C3a compared to the control patients (Figure 3B).
Furthermore, we investigated the target molecule of C3a,
namely C3aR, through GEP analysis. The expression of this
gene partially mirrors that of C3, with high levels in EM lesions
and low expression in the eutopic endometrium (Figure 3C). We
confirmed the C3aR expression in EM lesions by IHC
(Supplementary Figure 8).
Hypothesizing that C3a present in the peritoneal cavity of EM
patients could stimulate the MCs within the EM lesions, we
investigated the pattern distribution of MCs in the EM tissue. We
therefore stained human EM tissue sections with toluidine blue to
highlight MCs presence in the tissue. The histochemical analysis
confirmed that EM lesions were rich in MCs (Figures 3D, E),
compared to normal endometrium (Figure 3F). The IHC for C3a
on the same sections corroborated the presence of this
anaphylatoxin in EM lesions as well (Figures 3G, H) and
revealed the absence in normal tissue (Figure 3I).August 2021 | Volume 12 | Article 693118
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Loop of Inflammation Between MCs and
EM Cells
In order to mimic the cross-talk between EM cells and MCs and
understand the role of C3a, we set up a co-culture assay, seedingFrontiers in Immunology | www.frontiersin.org 7endometrial cell line (AN3CA) at the bottom of a 24-well plate
and placing the HMC-1 (a MC cell line) onto the upper chamber
of a transwell system (1 µm diameter pores), in the presence or
absence of a pool of EM-PF and/or a blocking anti-C3a antibody.




FIGURE 2 | In vivo syngeneic mouse model of EM. (A) Treatment regimen of C3 WT and gene-deficient mice for generating EM in vivo model. Five C3-/- and WT
mice each were injected (i.p.) with minced uterus of a donor mouse C3-/- and WT respectively; after 3 weeks, the peritoneal cyst formation was evaluated.
(B) Number of cysts counted in wild-type (WT) mice injected with WT endometrium (n = 5) or C3-/- injected with C3-/- endometrium (n = 5). Mann-Whitney test p =
0.03. (C, D) Representative images of cytocentrifuged peritoneal washing of untreated WT, EM-induced WT and C3-/- mice (respectively), stained with Giemsa and
counted with ImageJ software (Particle Analysis Tool) to obtain relative percentage between total leukocytes and mast cell (MC)/basophil number. MCs/basophils are
identified as blue big dots indicated by red arrows. Original magnification 100×. (E) Representative images of cytocentrifuged peritoneal lavage of EM-induced WT
mice stained with FITC-conjugated anti-mouse CD117. Original magnification 100×. (F) Biochemical characterization of tryptase enzyme present in peritoneal lavage
of WT vs C3-/- mice by ELISA. *p < 0.05.August 2021 | Volume 12 | Article 693118
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of C3. However, after HMC-1 stimulation with EM-PF, AN3CA
cells began to express higher quantities of C3 (Figure 4A).
Surprisingly, stimulation with EM-PF alone (in absence of HMC-
1) was not sufficient to increase C3 expression levels, in the absence
of HMC-1. A significant level of C3 production by AN3CA was
only evident following addition of HMC-1 stimulated by EM-PF,
showing C3 levels comparable to TNF-a stimulation (positive
control). Pre-incubation of EM-PF with a blocking monoclonalFrontiers in Immunology | www.frontiersin.org 8anti-C3a antibody completely abrogated the effect of EM-PF
stimulation, bringing C3 levels to the resting values (Figure 4B).
With a view to gauge a potential novel immunotherapeutic
approach for EM, we investigated in our co-culture model the
effect of three different anti-TNF-a antibodies. Infliximab and
Adalimumab (both in clinical use) showed a strong effect in
blocking C3 expression by AN3CA, whereas Certolizumab did
not block significantly the effects induced by the EM-PF on
HMC-1 cells (Figure 4C).FIGURE 3 | Peritoneal Fluids (PFs) derived from EM patients contained elevated levels of C3a that likely acts on MCs in the EM tissue. (A) Graphical representation
of the C3 cleavage and C3a formation. (B) C3a ELISA evaluation of PFs isolated from EM patients (n = 16) compared to control patient group (n = 8). (C) Histogram
representing C3AR1 mRNA expression in control endometrium (CE), patient endometrium (PE) and in different EM lesions (peritoneal, deep and ovarian EM). GEP
analysis, based on data extracted from GEO (GSE141549), highlighted a significantly higher expression of C3AR1 in EM lesions as compared to CE. ***p < 0.001,
****p < 0.0001 (Mann-Whitney U Test). (D, E) Toluidine blue staining of human EM tissue sections for the evaluation of MCs presence. Black arrows indicate MCs.
(F) Toluidine blue staining of secretive uterine endometrium revealed the absence of MCs. (G, H) Immunohistochemical analysis of C3a in EM tissue sections. AEC
(red) chromogen was used to visualize the binding of anti-human C3a antibodies. AEC (red) chromogen was used to visualize the binding of anti-human C3a
antibodies. Nuclei were counterstained blue with Harris Hematoxylin; scale bars, 50mm. (I) Immunoistochemical analysis of C3a in secretive uterine endometrium
revealed the absence of C3a.August 2021 | Volume 12 | Article 693118
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Dysregulation of the complement system has largely emerged as
an important mechanism in the pathogenesis of EM (32, 33),
regulating chronic inflammation and concurring as a
precipitating factor in EM-associated ovarian cancer (13).
Several complement components such as C3, C4A, C7, factor
D, factor B, factor H, and mannose-associated serine protease 1
(MASP1), are differentially expressed in EM compared to normal
uterine tissues (13). The most studied protein is C3 (34),
although its contribution in EM pathogenic mechanisms has
not been elucidated yet.
The presence of C3 in EM tissue was first highlighted in 1980
(35). Subsequent studies confirmed the presence of higher levels
of C3 in the EM lesions (13, 18, 19, 32, 33, 36–39). In the current
study, C3 was found to be widely distributed in the EM lesions
with variable intensity, being mostly localized in the glandular-
like structures and in the vessels. Despite detecting the presence
of C3 in both eutopic and ectopic endometrium (Figure 1),Frontiers in Immunology | www.frontiersin.org 9we noted a considerably stronger positivity of C3 in ectopic
endometrium of the ovary and the abdominal wall.
Different C3 expression levels between ectopic tissues and
normal uterus were also confirmed by RT-qPCR on mRNA
samples extracted directly from ovarian EM cysts (Figure 1F)
and primary cells isolated from the same district (Figures 1G, H).
In fact, C3 appeared to be produced locally and in higher amounts
in the ectopic tissues compared to the normal uterus. To gain a
more complete insight into the EM microenvironment, we also
considered the potential contribution of endothelial cells isolated
from EM lesions in the production of C3. However, we found out
that these cells were not responsible for the differential expression
of C3 transcript observed between EM tissue and normal uterus.
Another innovative element in the present study was the
attempt to elucidate the factors responsible for the increased C3
expression by the ectopic endometrial cells as compared to the
uterine endometrium (36). In fact, we hypothesized that the
inflammatory microenvironment found in EM lesions and in
the abdominal cavity might influence the local C3 production.A
B
C
FIGURE 4 | The co-culture of MCs with endometrial cells, in the presence of EM-PF, induced the expression of C3, which was inhibited by C3a blocking antibody.
(A) The C3 gene expression was evaluated by RT-qPCR on endometrial AN3CA cells alone (resting conditions), stimulated with TNF-a (+TNF-a) or with a pool of EM
peritoneal fluid (+EM-PF); or co-cultured with MCs alone (+HMC-1), or with EM-PF (+HMC-1+ EM-PF). Similar experiments were performed in the presence of anti-
C3a blocking antibody (B), or in the presence of anti-TNF-a blocking antibodies [(Infliximab, Adalimumab or Certolizumab), (C)]. In the left part of the figure the
graphical representations of the blocking co-culture experiments. Data are expressed as mean of three independent experiments conducted in double ± standard
error. *p < 0.05, **p < 0.01, n.s., not significant.August 2021 | Volume 12 | Article 693118
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endometrial cells is the PF rich in pro-inflammatory factors (39).
In particular, TNF-a concentrations in the PF are elevated in EM
patients and its concentration correlates with the severity and
stage of the disease (40, 41). Furthermore, TNF-a and IL-1b are
known to be elevated in EM milieu (39, 42). We confirmed that
the stimulation of endometrial cells with TNF-a (100 ng/mL),
and to a lesser extent with IL-1b (5 ng/mL), induced an enhanced
production of C3.
Based on these findings we set up an in vitro model of EM to
understand the pathogenic mechanisms through monitoring C3
expression by AN3CA cells under different conditions.
Surprisingly, the stimulation of normal endometrial cells with
EM-PF did not directly cause an increase in C3 gene expression,
suggesting that the concentration of TNF-a in the PF (around 50
pg/ml) was not sufficient for a direct endometrial cell activation.
Speculating on the source of an increased concentration of
TNF-a in the endometrial tissue, we examined a C3-/- mouse
model. Interestingly, no studies involving complement-deficient
animal models have been reported so far. Our mouse model
allowed us to primarily demonstrate that C3 deficient mice were
refractory to the development of endometriotic lesions, whereas
WT mice developed a higher number of EM cysts (Figure 2B),
suggesting that the lack of C3 prevented the EM cyst formation.
It is interesting to note that in a syngeneic mouse model, which
involved injection of normal uterus (and not EM lesion) in the
peritoneum, one would not expect availability of a reasonable
amount of locally synthesized C3. However, we still noticed
statistically significant differences in cyst formation, indicating
that the circulating C3 probably plays an important role in this
case. Moreover, we accidentally discovered the involvement of
MCs in the pathogenic mechanisms concerning C3, since the
WT mice were characterized by the presence of degranulated
MCs in PF, as demonstrated by the detection of a considerably
higher amount of tryptase, compared to C3-/- mice (Figure 2F).
It is largely considered that macrophages, among various
immune cells, exert a pivotal role in the pathogenesis of EM (22,
43, 44). These cells could be responsible for the local synthesis of C3
in EM lesions as well (45), but, since we did not notice differences in
mouse peritoneal washings and in co-culture experiments
(Supplementary Figure 9), we decided to focus only on MCs.
Several studies have demonstrated the involvement of MCs in
the EM lesion formation and progression (46, 47). In particular, a
recent study showed that the number of total MCs, as well as
activated MCs, was significantly increased in EM lesions in both
animal models and humans. An increased presence of activated
and degranulated MCs in deeply infiltrating EM and its close
histological relationship with nerves strongly suggest that MCs
contribute to the development of pain and hyperalgesia in EM,
possibly by a direct effect on the nerve structures (11). Based on
this growing evidence, the use of MC stabilizers and inhibitors
has also been proposed as a promising treatment for EM and its
associated pain (11, 47). The diffuse infiltration of numerous
MCs, accompanied also by increased presence of scattered
granules, has been frequently observed throughout the stromal
lesions, whereas in the eutopic endometrium and normal uterineFrontiers in Immunology | www.frontiersin.org 10serosa of the EM patients and controls, MCs were rarely detected
(12). Thus, in our study, EM lesions were found to be rich in
MCs (Figures 3D, E), compared to normal endometrium
(Figure 3F), as determined by toluidine blue histochemical
staining. A good proportion of MCs were localized around
blood vessels and in the fibrotic interstitium of endometrial
cysts, suggesting a particularly close relationship of MC
localization with fibrosis and adhesion (48).
The point of connection between C3 and MCs in EM
microenvironment could be the presence of C3a, one of the
most important stimuli for MC activation (49). C3a formation is
due to complement activation in the EM microenvironment,
previously described by the presence of different complement
components and complement activation products, such as C1q,
MBL, C1INH, C4 and C3c SC5b-9, in the PFs and in the sera of
EM women (14, 50). One of the most reasonable explanation
could be the setting off of the coagulation cascade, which is
caused by the typical periodic bleeding in the EM tissue.
Interaction between complement, coagulation and contact
systems are well-established. Thrombin, FXIa, FXa, FXa and
plasmin cleave C3 (and C5) to C3a and C3b; activated platelets
are also involved in C3 cleavage (51–53). Another activator of the
C3 is heme that is released from hemoglobin during hemolysis;
heme induces deposition of C3 fragments on the erythrocytes
(54). Alternative pathway activation can occur through its up-
regulator, properdin, binding to activated platelets promoting C3
(H2O) recruitment and complement activation (55). In addition,
stimulation of endothelial cells by C3a or other factors promptly
induces expression of P-selectin, which by binding to C3b,
induces the formation of C3 convertases (56). Recently,
MASP-2 has been shown to cleave C3 in the absence of C2
and C4, in addition to and cleaving prothrombin into active
thrombin (57–59).
We confirmed the presence of higher levels of C3a in the EM-
PF compared to control non-EM healthy women (Figure 3B); we
also detected C3a in EM tissue samples but not in normal
endometrium (Figures 3G–I). Moreover, in the co-culture
assay, the pre-incubation of EM-PF with a blocking
monoclonal anti-C3a antibody completely abrogated the effect
of EM-PF stimulation, bringing C3 levels to resting values.
C3a present in the EM-PF can act, through C3aR interaction,
which is abundantly expressed on the MCs present in the EM
tissue (10, 36). C3a involvement in EM has also been suggested
by previous evidence highlighting its correlation with chemokine
CCL8 (60), a promotor of the cross-talk between endometrial
cells and MCs in the development of EM through the binding to
its receptor CCR1, characterized by over-expression in the
ectopic endometrium and colocalization with blood vessels in
ovarian endometriomas (61).CONCLUSIONS
In conclusion, using C3-/- murine model of EM, we demonstrated
a pivotal role of C3 in the progression of EM lesions. It appears
normal endometrial cells, under pro-inflammatory stimuli, startAugust 2021 | Volume 12 | Article 693118
Agostinis et al. Role of C3 in Endometriosisto produce C3. C3a, locally produced by complement activation
and stimulated by the pro-inflammatory milieu, seems to recruit
and activate MCs in the EM lesions, which can have a pathogenic
consequence in the ectopic EM by releasing histamine and TNF-
a as well as additional inflammatory factors. C3 appears,
therefore, as a central factor in a regulatory feed forward loop,
which is able to amplify the inflammatory microenvironment, in
which the MCs are protagonists. This study opens up a new
window for the identification of novel therapeutic targets for
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